Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

MLA

Chan, Dick C., et al. “Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 7, July 2018, pp. 1644–55. EBSCOhost, https://doi.org/10.1161/ATVBAHA.118.310882.

APA

Chan, D. C., Watts, G. F., Somaratne, R., Wasserman, S. M., Scott, R., & Barrett, P. H. R. (2018). Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(7), 1644–1655. https://doi.org/10.1161/ATVBAHA.118.310882

Chicago

Chan, Dick C, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott, and P Hugh R Barrett. 2018. “Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.” Arteriosclerosis, Thrombosis, and Vascular Biology 38 (7): 1644–55. doi:10.1161/ATVBAHA.118.310882.